ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bone Marrow Mesenchymal Stem Cell Hydrogel-Mediated Fibroblast Reprogramming Restores Intestinal Function in Adhesive Small Bowel Obstruction.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone Marrow Mesenchymal Stem Cell Hydrogel-Mediated Fibroblast Reprogramming Restores Intestinal Function in Adhesive Small Bowel Obstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Adhesive small bowel obstruction (ASBO) is a surgical complication characterized by intestinal stenosis due to ectopic fibroblast activation following serosal injury. This study demonstrates that bone marrow mesenchymal stem cells encapsulated in a silk hydrogel (BMSC@Gel) not only prevent tissue adhesion but also restores physiological functions in both mouse tissues and human-derived organoids. BMSCs exert dual regulatory effects on the obstructed intestinal microenvironment. First, they preferentially differentiate into proliferating fibroblasts (FBs) expressing Top2a, Stmn1, and Spp1 rather than inflammatory FBs marked by Adamdec1, Mmp3, and Igfbp3. Second, BMSC-derived exosomes suppress the inflammatory microenvironment, thereby maintaining intestinal homeostasis. Furthermore, BMSCs modulate fibroblast phenotypes and intracellular interactions and inhibit the TGF-β1/Smad3 signaling pathway during fibrosis development, thereby reversing the onset of ASBO. Collectively, these findings highlight BMSC@Gel as a promising therapeutic strategy for the prevention of ASBO in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.